Back to search

Article

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial

2024-11-06

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer’s disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a3834342-7a11-5ff6-ad43-3830de18396c
DOI
10.1101/2024.10.29.24316289
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialDOI 10.1101/2024.10.29.24316289
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Semantic proximity
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity
Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brainSemantic proximity
A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Intracisternal Engineered Autologous Exosomes (NV-101) to Restore Neuronal Proteostasis in Early Alzheimer’s Disease: The RESTORE ProtocolSemantic proximity
Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.Semantic proximity
Molecular Therapeutics in Development to Treat Alzheimer’s DiseaseSemantic proximity
Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity
The Alzheimer’s disease drug development landscapeSemantic proximity
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.Semantic proximity
CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signaturesSemantic proximity
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.Semantic proximity
Select a neighboring publication to make it the new centre.